http://orcid.org/0000-0003-0169-9899
References
- Gurney SM, Scott KS, Kacinko SL, et al. Pharmacology, toxicology, and adverse effects of synthetic cannabinoid drugs. Forensic Sci Rev. 2014;26:53–78.
- Takayama T, Suzuki M, Todoroki K, et al. UPLC/ESI-MS/MS-based determination of metabolism of several new illicit drugs, ADB-FUBINACA, AB-FUBINACA, AB-PINACA, QUPIC, 5F-QUPIC and α-PVT, by human liver microsome. Biomed Chromatogr. 2014;28:831–838.
- Vikingsson S, Gréen H, Brinkhagen L, et al. Identification of AB-FUBINACA metabolites in authentic urine samples suitable as urinary markers of drug intake using liquid chromatography quadrupole tandem time of flight mass spectrometry. Drug Test Analysis. 2016;8:950–956.
- Buchler IP, Hayes MJ, Hegde SG, et al. Indazole derivatives. Patent: WO/2009/106982. Sept. 2009.
- Uchiyama N, Matsuda S, Wakana D, et al. New cannabimimetic indazole derivatives, N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) and N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA) identified as designer drugs in illegal products. Forensic Toxicol. 2013;31:93–100.
- Uchiyama N, Matsuda S, Kawamura M, et al. Two new-type cannabimimetic quinolinyl carboxylates, QUPIC and QUCHIC, two new cannabimimetic carboxamide derivatives, ADB-FUBINACA and ADBICA, and five synthetic cannabinoids detected with a thiophene derivative α-PVT and an opioid receptor agonist AH-7921 identified in illegal products. Forensic Toxicol. 2013;31:223–240.
- Castaneto MS, Gorelick DA, Desrosiers NA, et al. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend. 2014;144:12–41.
- Trecki J, Gerona RR, Schwartz MD. Synthetic cannabinoid-related illnesses and deaths. N Engl J Med. 2015;373:103–107.
- Fernandez D, Hammer J, De Olano J, et al. A synthetic cannabinoid receptor agonist (AB-FUBINACA)-associated fatality. 36th International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) 24–27 May, 2016, Madrid, Spain. Clin Toxicol. 2016;54:344–519.
- Shanks KG, Clark W, Behonick G. Death associated with the use of the synthetic cannabinoid ADB-FUBINACA. J Anal Toxicol. 2016;40:236–239.
- Klavž J, Gorenjak M, Marinšek M. Suicide attempt with a mix of synthetic cannabinoids and synthetic cathinones: Case report of non-fatal intoxication with AB-CHMINACA, AB-FUBINACA, alpha-PHP, alpha-PVP and 4-CMC. Forensic Sci Int. 2016;265:121–124.
- Hermanns-Clausen M, Kneisel S, Szabo B, et al. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction. 2013;108:534–544.
- Lapoint J, James LP, Moran CL, et al. Severe toxicity following synthetic cannabinoid ingestion. Clin Toxicol. 2011;49:760–764.
- Aryana A, Williams MA. Marijuana as a trigger of cardiovascular events: speculation or scientific certainty? Int J Cardiol. 2007;118:141–144.
- Murakami T, Iwamuro Y, Ishimaru R, et al. Differentiation of AB-FUBINACA positional isomers by the abundance of product ions using electron ionization-triple quadrupole mass spectrometry. J Mass Spectrom. 2016;51:1016–1022.